BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cava C, Bertoli G, Castiglioni I. In Silico Discovery of Candidate Drugs against Covid-19. Viruses 2020;12:E404. [PMID: 32268515 DOI: 10.3390/v12040404] [Cited by in Crossref: 87] [Cited by in F6Publishing: 61] [Article Influence: 43.5] [Reference Citation Analysis]
Number Citing Articles
1 Pant S, Jena NR. Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors. Eur J Pharm Sci 2021;167:106012. [PMID: 34543728 DOI: 10.1016/j.ejps.2021.106012] [Reference Citation Analysis]
2 Scalise M, Indiveri C. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19. SLAS DISCOVERY: Advancing the Science of Drug Discovery 2020;25:1171-3. [DOI: 10.1177/2472555220934421] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 [DOI: 10.1101/2020.07.09.20150235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tripathi G, Singh AK, Kumar A. Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application. COC 2020;24:1555-81. [DOI: 10.2174/1570179417999200628035645] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Chowdhury N, Bagchi A. Identification of the binding interactions of some novel antiviral compounds against Nsp1 protein from SARS-CoV-2 (COVID-19) through high throughput screening. J Biomol Struct Dyn 2021;:1-8. [PMID: 33612076 DOI: 10.1080/07391102.2021.1887763] [Reference Citation Analysis]
6 Loas G, Le Corre P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2021;14:691. [PMID: 34358117 DOI: 10.3390/ph14070691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hu S, Jiang S, Qi X, Bai R, Ye XY, Xie T. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. Drug Dev Res 2021. [PMID: 34762760 DOI: 10.1002/ddr.21895] [Reference Citation Analysis]
8 Cava C, Bertoli G, Castiglioni I. A protein interaction map identifies existing drugs targeting SARS-CoV-2. BMC Pharmacol Toxicol 2020;21:65. [PMID: 32883368 DOI: 10.1186/s40360-020-00444-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 [DOI: 10.1101/2020.07.09.196519] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Bejan CA, Cahill KN, Staso PJ, Choi L, Peterson JF, Phillips EJ. DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing. Clin Pharmacol Ther 2021. [PMID: 34314511 DOI: 10.1002/cpt.2376] [Reference Citation Analysis]
11 Keretsu S, Bhujbal SP, Cho SJ. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Sci Rep 2020;10:17716. [PMID: 33077821 DOI: 10.1038/s41598-020-74468-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
12 Dakal TC. SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19. Immunobiology 2021;226:152021. [PMID: 33232865 DOI: 10.1016/j.imbio.2020.152021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
13 de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. bioRxiv 2021:2020. [PMID: 32869028 DOI: 10.1101/2020.08.28.272880] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
14 Ratre YK, Kahar N, Bhaskar LVKS, Bhattacharya A, Verma HK. Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective. 3 Biotech 2021;11:94. [PMID: 33520580 DOI: 10.1007/s13205-021-02657-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kuleshov MV, Clarke DJB, Kropiwnicki E, Jagodnik KM, Bartal A, Evangelista JE, Zhou A, Ferguson LB, Lachmann A, Ma'ayan A. The COVID-19 Gene and Drug Set Library. Res Sq 2020:rs. [PMID: 32702729 DOI: 10.21203/rs.3.rs-28582/v1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Le BL, Andreoletti G, Oskotsky T, Vallejo-Gracia A, Rosales R, Yu K, Kosti I, Leon KE, Bunis DG, Li C, Kumar GR, White KM, García-Sastre A, Ott M, Sirota M. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Sci Rep 2021;11:12310. [PMID: 34112877 DOI: 10.1038/s41598-021-91625-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bagheri A, Moezzi SMI, Mosaddeghi P, Nadimi Parashkouhi S, Fazel Hoseini SM, Badakhshan F, Negahdaripour M. Interferon-inducer antivirals: Potential candidates to combat COVID-19. Int Immunopharmacol 2021;91:107245. [PMID: 33348292 DOI: 10.1016/j.intimp.2020.107245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
18 Kleandrova VV, Scotti MT, Speck-Planche A. Indirect-Acting Pan-Antivirals vs. Respiratory Viruses: A Fresh Perspective on Computational Multi-Target Drug Discovery. Curr Top Med Chem 2021. [PMID: 34636311 DOI: 10.2174/1568026621666211012110819] [Reference Citation Analysis]
19 Xu XG, Wang H, Wang SY, Zhang J, Sun C, Wei MX, Yan J, Mao GX. Predictive Analysis of Susceptibility of Different Species to SARS-CoV-2 based on ACE2 Receptors. Biomed Environ Sci 2020;33:877-81. [PMID: 33771243 DOI: 10.3967/bes2020.120] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Ramesh M, Anand K, Shahbaaz M, Abdellattif MH. Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19. Front Mol Biosci 2021;8:648232. [PMID: 34322517 DOI: 10.3389/fmolb.2021.648232] [Reference Citation Analysis]
21 Shao H, Ghaly HSA, Varamini P. Coronavirus Disease 2019: An Overview of the Complications and Management. INNOSC Theranostics and Pharmacological Sciences. [DOI: 10.36922/itps.v4i1.1037] [Reference Citation Analysis]
22 Liscano Y, Oñate-Garzón J, Ocampo-Ibáñez ID. In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. Molecules 2020;25:E5535. [PMID: 33255849 DOI: 10.3390/molecules25235535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Oluwasayo Peter A, Onifade OF, Adeboyega AE. Therapeutic capability of five active compounds in typical African medicinal plants against main proteases of SARS-CoV-2 by computational approach. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.100964] [Reference Citation Analysis]
24 Durojaiye AB, Clarke JD, Stamatiades GA, Wang C. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies. J Biomol Struct Dyn 2021;39:4547-54. [PMID: 32538276 DOI: 10.1080/07391102.2020.1777904] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
25 Zhang R, Hristovski D, Schutte D, Kastrin A, Fiszman M, Kilicoglu H. Drug repurposing for COVID-19 via knowledge graph completion. J Biomed Inform 2021;115:103696. [PMID: 33571675 DOI: 10.1016/j.jbi.2021.103696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life Sci 2020;254:117775. [PMID: 32418894 DOI: 10.1016/j.lfs.2020.117775] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
27 Dehelean CA, Lazureanu V, Coricovac D, Mioc M, Oancea R, Marcovici I, Pinzaru I, Soica C, Tsatsakis AM, Cretu O. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. J Clin Med 2020;9:E2084. [PMID: 32630746 DOI: 10.3390/jcm9072084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
28 Nain Z, Rana HK, Liò P, Islam SMS, Summers MA, Moni MA. Pathogenetic profiling of COVID-19 and SARS-like viruses. Brief Bioinform 2021;22:1175-96. [PMID: 32778874 DOI: 10.1093/bib/bbaa173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
29 Langarizadeh MA, Ranjbar Tavakoli M, Abiri A, Ghasempour A, Rezaei M, Ameri A. A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms. EXCLI J 2021;20:339-65. [PMID: 33746666 DOI: 10.17179/excli2020-3196] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
30 Çakır B, Okuyan B, Şener G, Tunali-Akbay T. Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): In silico analysis. Eur J Pharmacol 2021;891:173781. [PMID: 33271151 DOI: 10.1016/j.ejphar.2020.173781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Wang X, Guan Y. COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 2021;41:5-28. [PMID: 32864815 DOI: 10.1002/med.21728] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
32 Senapati S, Banerjee P, Bhagavatula S, Kushwaha PP, Kumar S. Contributions of human ACE2 and TMPRSS2 in determining host–pathogen interaction of COVID-19. J Genet 2021;100. [DOI: 10.1007/s12041-021-01262-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
33 Fayyazi N, Mostashari-Rad T, Ghasemi JB, Ardakani MM, Kobarfard F. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19. J Biomol Struct Dyn 2021;:1-22. [PMID: 34405765 DOI: 10.1080/07391102.2021.1965914] [Reference Citation Analysis]
34 Jena NR, Pant S, Srivastava HK. Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2. J Biomol Struct Dyn 2021;:1-17. [PMID: 33565387 DOI: 10.1080/07391102.2021.1883112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 De Toni L, Garolla A, Di Nisio A, Rocca MS, Foresta C. Caution in the management of SARS-CoV-2 infection in males. Andrology 2021;9:27-9. [PMID: 32452644 DOI: 10.1111/andr.12829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Pratama MRF, Poerwono H, Siswodihardjo S. Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors. Pharm Sci 2020;26:S63-77. [DOI: 10.34172/ps.2020.57] [Reference Citation Analysis]
37 Bejan CA, Cahill KN, Staso PJ, Choi L, Peterson JF, Phillips EJ. DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19. medRxiv 2021:2021. [PMID: 33564788 DOI: 10.1101/2021.02.04.21251169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Huang Y, Zheng WJ, Ni YS, Li MS, Chen JK, Liu XH, Tan XH, Li JQ. Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology. BioData Min 2020;13:15. [PMID: 32983259 DOI: 10.1186/s13040-020-00225-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sen S, Sanders EC, Gabriel KN, Miller BM, Isoda HM, Salcedo GS, Garrido JE, Dyer RP, Nakajima R, Jain A, Caldaruse AM, Santos AM, Bhuvan K, Tifrea DF, Ricks-Oddie JL, Felgner PL, Edwards RA, Majumdar S, Weiss GA. Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score. bioRxiv 2021:2020. [PMID: 33083803 DOI: 10.1101/2020.10.15.341743] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives. Restor Neurol Neurosci 2020;38:343-54. [PMID: 32597823 DOI: 10.3233/RNN-201042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
41 Sharma M, Prasher P, Mehta M, Zacconi FC, Singh Y, Kapoor DN, Dureja H, Pardhi DM, Tambuwala MM, Gupta G, Chellappan DK, Dua K, Satija S. Probing 3CL protease: Rationally designed chemical moieties for COVID-19. Drug Dev Res 2020. [PMID: 32729640 DOI: 10.1002/ddr.21724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jakhmola Mani R, Sehgal N, Dogra N, Saxena S, Pande Katare D. Deciphering underlying mechanism of Sars-CoV-2 infection in humans and revealing the therapeutic potential of bioactive constituents from Nigella sativa to combat COVID19: in-silico study. J Biomol Struct Dyn 2020;:1-13. [PMID: 33111624 DOI: 10.1080/07391102.2020.1839560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Le BL, Andreoletti G, Oskotsky T, Vallejo-Gracia A, Rosales R, Yu K, Kosti I, Leon KE, Bunis DG, Li C, Kumar GR, White KM, García-Sastre A, Ott M, Sirota M. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Res Sq 2021:rs. [PMID: 33821262 DOI: 10.21203/rs.3.rs-333578/v1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sarangi MK, Padhi S, Dheeman S, Karn SK, Patel LD, Yi DK, Nanda SS. Diagnosis, prevention, and treatment of coronavirus disease: a review. Expert Rev Anti Infect Ther 2021;:1-24. [PMID: 34151679 DOI: 10.1080/14787210.2021.1944103] [Reference Citation Analysis]
45 Karami H, Derakhshani A, Ghasemigol M, Fereidouni M, Miri-Moghaddam E, Baradaran B, Tabrizi NJ, Najafi S, Solimando AG, Marsh LM, Silvestris N, De Summa S, Paradiso AV, Racanelli V, Safarpour H. Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. J Clin Med 2021;10:3567. [PMID: 34441862 DOI: 10.3390/jcm10163567] [Reference Citation Analysis]
46 Adhami M, Sadeghi B, Rezapour A, Haghdoost AA, MotieGhader H. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis. BMC Biotechnol 2021;21:22. [PMID: 33711981 DOI: 10.1186/s12896-021-00680-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Rodríguez-Tomàs E, Iftimie S, Castañé H, Baiges-Gaya G, Hernández-Aguilera A, González-Viñas M, Castro A, Camps J, Joven J. Clinical Performance of Paraoxonase-1-Related Variables and Novel Markers of Inflammation in Coronavirus Disease-19. A Machine Learning Approach. Antioxidants (Basel) 2021;10:991. [PMID: 34205807 DOI: 10.3390/antiox10060991] [Reference Citation Analysis]
48 Raju R, V P, Biatris PS, J SJUC. Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials. Futur J Pharm Sci 2021;7:67. [PMID: 33754123 DOI: 10.1186/s43094-021-00217-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
49 Hsieh KL, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, Tang J, Kim Y. Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation. Res Sq 2020:rs. [PMID: 33330858 DOI: 10.21203/rs.3.rs-114758/v1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Sakr MM, Elsayed NS, El-Housseiny GS. Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. Microb Pathog 2021;154:104809. [PMID: 33647446 DOI: 10.1016/j.micpath.2021.104809] [Reference Citation Analysis]
51 Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, Leone M, La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, Rolain JM, Parola P, Lagier JC, Brouqui P, Raoult D. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol 2020;16:1159-84. [PMID: 33356661 DOI: 10.1080/1744666X.2021.1847640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
52 Luo L, Qiu Q, Huang F, Liu K, Lan Y, Li X, Huang Y, Cui L, Luo H. Drug repurposing against coronavirus disease 2019 (COVID-19): A review. J Pharm Anal 2021. [PMID: 34513115 DOI: 10.1016/j.jpha.2021.09.001] [Reference Citation Analysis]
53 Ambrocio-Ortiz E, Pérez-Rubio G, Del Ángel-Pablo AD, Buendía-Roldán I, Chávez-Galán L, Hernández-Zenteno RJ, Ramírez-Venegas A, Rojas-Serrano J, Mejía M, Pérez-Padilla R, Guadarrama-Pérez C, Falfán-Valencia R. Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Pharmaceuticals (Basel) 2021;14:805. [PMID: 34451902 DOI: 10.3390/ph14080805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Iyer K, Chand K, Mitra A, Trivedi J, Mitra D. Diversity in heat shock protein families: functional implications in virus infection with a comprehensive insight of their role in the HIV-1 life cycle. Cell Stress Chaperones 2021. [PMID: 34318439 DOI: 10.1007/s12192-021-01223-3] [Reference Citation Analysis]
55 MohammadiPeyhani H, Chiappino-Pepe A, Haddadi K, Hafner J, Hadadi N, Hatzimanikatis V. NICEdrug.ch, a workflow for rational drug design and systems-level analysis of drug metabolism. Elife 2021;10:e65543. [PMID: 34340747 DOI: 10.7554/eLife.65543] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 El Kantar S, Nehmeh B, Saad P, Mitri G, Estephan C, Mroueh M, Akoury E, Taleb RI. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today 2020:S1359-6446(20)30307-X. [PMID: 32801052 DOI: 10.1016/j.drudis.2020.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 Nambou K, Anakpa M. Deciphering the co-adaptation of codon usage between respiratory coronaviruses and their human host uncovers candidate therapeutics for COVID-19. Infect Genet Evol 2020;85:104471. [PMID: 32707288 DOI: 10.1016/j.meegid.2020.104471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
58 Camps J, Castañé H, Rodríguez-Tomàs E, Baiges-Gaya G, Hernández-Aguilera A, Arenas M, Iftimie S, Joven J. On the Role of Paraoxonase-1 and Chemokine Ligand 2 (C-C motif) in Metabolic Alterations Linked to Inflammation and Disease. A 2021 Update. Biomolecules 2021;11:971. [PMID: 34356595 DOI: 10.3390/biom11070971] [Reference Citation Analysis]
59 Le Corre P, Loas G. Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection? J Clin Pharm Ther 2021. [PMID: 33645763 DOI: 10.1111/jcpt.13390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
60 Aronskyy I, Masoudi-Sobhanzadeh Y, Cappuccio A, Zaslavsky E. Advances in the computational landscape for repurposed drugs against COVID-19. Drug Discov Today 2021:S1359-6446(21)00335-4. [PMID: 34339864 DOI: 10.1016/j.drudis.2021.07.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Barh D, Tiwari S, Weener ME, Azevedo V, Góes-Neto A, Gromiha MM, Ghosh P. Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19. Comput Biol Med 2020;126:104051. [PMID: 33131530 DOI: 10.1016/j.compbiomed.2020.104051] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
62 Cava C, Bertoli G, Castiglioni I. Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation. Future Virol 2021. [PMID: 34306168 DOI: 10.2217/fvl-2020-0392] [Reference Citation Analysis]
63 Rabie AM. Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease. ACS Omega. [DOI: 10.1021/acsomega.1c07095] [Reference Citation Analysis]
64 Sur VP, Sen MK, Komrskova K. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease. Molecules 2021;26:6199. [PMID: 34684780 DOI: 10.3390/molecules26206199] [Reference Citation Analysis]
65 Yu W, Bai Y, Raha A, Su Z, Geng F. Integrative In Silico Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2. Front Bioinform 2022;1:763540. [DOI: 10.3389/fbinf.2021.763540] [Reference Citation Analysis]
66 Wang R, Bikov A, Fowler SJ. Treating asthma in the COVID-19 pandemic. Thorax 2020;75:822-3. [PMID: 32522762 DOI: 10.1136/thoraxjnl-2020-215118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
67 Sheik Amamuddy O, Verkhivker GM, Tastan Bishop Ö. Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 Mpro. J Chem Inf Model 2020;60:5080-102. [PMID: 32853525 DOI: 10.1021/acs.jcim.0c00634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
68 Kumavath R, Barh D, Andrade BS, Imchen M, Aburjaile FF, Ch A, Rodrigues DLN, Tiwari S, Alzahrani KJ, Góes-Neto A, Weener ME, Ghosh P, Azevedo V. The Spike of SARS-CoV-2: Uniqueness and Applications. Front Immunol 2021;12:663912. [PMID: 34305894 DOI: 10.3389/fimmu.2021.663912] [Reference Citation Analysis]
69 Tsatsakis A, Petrakis D, Nikolouzakis TK, Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis C, Aschner M, Hernández AF. COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence. Food Chem Toxicol 2020;141:111418. [PMID: 32437891 DOI: 10.1016/j.fct.2020.111418] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 26.0] [Reference Citation Analysis]
70 Kuleshov MV, Stein DJ, Clarke DJB, Kropiwnicki E, Jagodnik KM, Bartal A, Evangelista JE, Hom J, Cheng M, Bailey A, Zhou A, Ferguson LB, Lachmann A, Ma'ayan A. The COVID-19 Drug and Gene Set Library. Patterns (N Y) 2020;1:100090. [PMID: 32838343 DOI: 10.1016/j.patter.2020.100090] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
71 Hernández Cordero AI, Li X, Yang CX, Milne S, Bossé Y, Joubert P, Timens W, van den Berge M, Nickle D, Hao K, Sin DD. Gene expression network analysis provides potential targets against SARS-CoV-2. Sci Rep 2020;10:21863. [PMID: 33318519 DOI: 10.1038/s41598-020-78818-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]